Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Evangelos Fergadis"'
Autor:
Georgios I. Papageorgiou, Evangelos Fergadis, Nikos Skouteris, Evridiki Christakos, Sergios A. Tsakatikas, Evangelos Lianos, Christos Kosmas
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Poly-ADP ribose polymerase (PARP) inhibitors are constantly increasing in their indications for use as anti-cancer treatment in various neoplasms, the majority of which are linked with BRCA deficiency. Preclinical data support the investigation of PA
Externí odkaz:
https://doaj.org/article/d0462d14688f4ca3bc41ba28ea0ba502
Publikováno v:
BMJ Case Reports. 16:e254688
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fc42f76f8338329bbcecb9d0daef5db
https://doi.org/10.1136/bcr-2023-254688
https://doi.org/10.1136/bcr-2023-254688
Autor:
Anastasios Grivas, Maria Karakosta, Evangelos Fergadis, Evangelos Lianos, Aikaterini Kosma, Eleftheria Kranidioti, Aggelos Athanasopoulos, George K. Dimitriadis, Abraam Assi, Constantinos Miltiadous, Christos Kosmas
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e50-e57
Background An appreciable proportion of patients in need of salvage high-dose chemotherapy (HDC) and autologous peripheral blood stem cell (PBSC) transplantation (PBSCT) fail to mobilize adequate numbers of hematopoietic progenitors, and plerixafor i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e62b5a8555d832d9578ed1c5bb1035b
https://doi.org/10.1016/j.clml.2019.11.022
https://doi.org/10.1016/j.clml.2019.11.022
Autor:
Christos Valavanis, Evridiki Christakos, Gabriela Stanc, Georgios I Papageorgiou, Christos Kosmas, Efthymia Souka, Aikaterini Filippakou, Sergios Tsakatikas, Evangelia Papantoni, Evangelos Fergadis, Nikos Skouteris
Publikováno v:
Anti-cancer drugs. 33(2)
Monoclonal antibodies against programmed cell death protein 1 (PD-1) and PD-1 ligand 1 (PD-L1) are the main representatives in the field of immunotherapy and their indications are constantly increasing in medical oncology and hematology during the la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::284d151544bef430452ca867f62609dc
https://pubmed.ncbi.nlm.nih.gov/34538865
https://pubmed.ncbi.nlm.nih.gov/34538865
Autor:
Evangelos Fergadis, Niki Gavrielatou, Aggelos Athanasopoulos, Nikos Skouteris, Evangelos Lianos, Christos Kosmas
Publikováno v:
Anti-cancer drugs. 30(2)
Salvage high-dose chemotherapy (HDC) together with autologous hematopoietic stem cell (HSC) transplantation (ASCT) represents a curative treatment option for patients with relapsed/refractory germ-cell tumor. Usually, 2-3 cycles of HDC are administer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7858af95563335c00eea092637e0b66
https://pubmed.ncbi.nlm.nih.gov/30489289
https://pubmed.ncbi.nlm.nih.gov/30489289